Country's biggest drug maker, Ranbaxy Laboratories Ltd on Wednesday said a US Appeals Court has ruled in its favour in the patent infringement case with Pfizer for cholesterol-lowering drug Atorvastatin (Lipitor).
Ranbaxy Laboratories Ltd on Tuesday launched its approved generic formulation of Clarithromycin immediate release tablets in the US market.
United States' Food and Drug Administration has granted approval to Ranbaxy Laboratories Ltd to manufacture and market 40 mg capsules of Fluoxetine, a drug used in treatment of obsessive-compulsive disorders.\n\n
Pharma major, Ranbaxy Laboratories Ltd has entered into a joint venture agreement with South African Community Investment Holdings to market and sell its range of Anti-Retroviral products in African markets.
Close on the heels of a US district court ruling against its patent challenge of Pfizer's Lipitor, Ranbaxy Laboratories Ltd on Friday said it had entered into an out of court settlement with Cephalon Inc
The Indian major is eyeing German Merck's generic drug business.
Ranbaxy Laboratories Ltd launched an anti-retroviral product, ABACAVIR, in India. The product, bioequivalent to the innovator brand, will be marketed in India under the brand name VIROL as 300 mg tablet formulation.
Ranbaxy Laboratories Ltd on Wednesday said that it has received $4 million from German pharma company Schwarz Pharma AG for further progress on the development of RBx 2258 molecule.
Ranbaxy Laboratories Ltd today said it has received tentative approval from the US Food and Drug Administration to manufacture and market Glimepiride tablets of 1 mg, 2 mg, 4 mg and 8 mg.
Ranbaxy Laboratories Ltd said on Thursday that it has bagged the US Food and Drug Administration's approval for manufacturing and marketing Loratadine and Pseudoephedrine Sulfate Extended-release tablets.
Ranbaxy Laboratories Ltd on Friday raised its equity stake to 50 per cent in Nihon Pharmaceutical Industry.
Ranbaxy Laboratories Ltd, India's top drugmaker by sales, said it expected to get US approvals for a paediatric dosage of its generic version of Augmentin, GlaxoSmithKline's blockbuster antibiotic, within a month.\n\n\n\n
Ranbaxy Laboratories Ltd on Friday said it has received approval from the US Food and Drug Administration to manufacture and market multiple dosages of anti-diabetes drug Glimepiride tablets.
A random check had found that tests failed to prove the medicines were same as the patented drugs.\n
Ranbaxy Laboratories Ltd will acquire RPG Aventis SA along with its fully-owned subsidiary, OPIH SARL, in France for an undisclosed sum.
Ranbaxy Laboratories Ltd on Monday said Nihon Pharmaceuticals Industry Ltd, a JV between the company and Nippon Chemiphar Ltd, has launched its first co-developed product Vogseal 0.2mg and 0.3mg tablets in Japan.\n\n
Ranbaxy Laboratories Ltd is likely to post over 20 per cent growth in turnover for the year ending December 31, 2004, the company's chief executive officer and managing director Brian Tempest said on Tuesday.
Indian drugmakers' domestic sales of ready-to-take medicines in January-March could be lower than expected as distributors suspended stocking in anticipation of a new value-added tax system coming into force, analysts and industry members said.\n\n\n\n
Indian drugmaker Ranbaxy Laboratories Ltd has received approval from the US Food and Drug Administration to market an oral suspension form of Warner Chilcott's Duricef antibiotic, the Bombay Stock Exchange
Ranbaxy Laboratories Ltd, which has profited handsomely by selling generic drugs in the United States, said on Tuesday it would increase its R&D spending by about 60 per cent over the next five years.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances